(ABOS)
NMS – Real vaqt narxi. Valyuta: USD
2.26
-0.29 (-11.37%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
2.26
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 6:31 PM EDT

NMS – Real vaqt narxi. Valyuta: USD
2.26
-0.29 (-11.37%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
2.26
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 6:31 PM EDT
Acumen Pharmaceuticals, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Altsgeymer kasalligini davolash uchun mo'ljallangan terapiyalarni ishlab chiqadi. Kompaniya eriydigan amiloid-beta oligomerlariga qarshi ta'sir qiluvchi, INTERCEPT-AD 1-faza klinik sinovini yakunlagan va ALTITUDE-AD 2-faza klinik sinovida bo'lgan rekombinant insonlashtirilgan immunoglobulin gamma 2 bo'lgan Sabirnetug (ACU193) nomli mo'ljallangan immunoterapiya dorisi nomzodini ishlab chiqishga qaratilgan. Kompaniya Sabirnetugning teri ostiga yuboriladigan shaklini ishlab chiqish uchun Halozyme, Inc. bilan hamkorlik va litsenziyalash shartnomasiga ega. Acumen Pharmaceuticals, Inc. 1996 yilda tashkil etilgan va shtab-kvartirasi Nyu-Ton, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Caleb E. Finch Ph.D. | Co-Founder |
| Dr. Grant A. Krafft Ph.D. | Co-Founder |
| Dr. James Doherty Ph.D. | President & Chief Development Officer |
| Dr. William L. Klein Ph.D. | Co-Founder |
| Mr. Daniel J. O'Connell M.B.A. | CEO & Director |
| Mr. Derek M. Meisner Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Matt Zuga | CFO & Chief Business Officer |
| Mr. Russell Barton M.S. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-16 | 8-K | abos-20260313.htm |
| 2026-01-12 | 8-K | abos-20260112.htm |
| 2025-11-12 | 8-K | abos-20251112.htm |
| 2025-11-10 | 8-K | abos-20251106.htm |
| 2025-08-12 | 10-Q | abos-20250630.htm |
| 2025-07-15 | 8-K | abos-20250715.htm |
| 2025-06-05 | 8-K | abos-20250604.htm |
| 2025-05-13 | 8-K | abos-20250513.htm |
| 2025-04-23 | DEFA14A | defa14a2025.htm |
| 2025-03-27 | S-8 | acumenpharma-sx82025.htm |
| Chief Operating Officer |
| Ms. Alex Braun M.B.A. | VP & Head of Investor Relations |
| Ms. Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller |